|
Volumn 389, Issue 10088, 2017, Pages 2448-2449
|
Immune oncology in hepatocellular carcinoma—hype and hope
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
NIVOLUMAB;
PROGRAMMED DEATH 1 LIGAND 1;
PROGRAMMED DEATH 1 RECEPTOR;
REGORAFENIB;
SORAFENIB;
TICILIMUMAB;
ANTINEOPLASTIC AGENT;
CARBANILAMIDE DERIVATIVE;
NICOTINAMIDE;
PROTEIN KINASE INHIBITOR;
PYRIDINE DERIVATIVE;
ADOPTIVE IMMUNOTHERAPY;
ANTINEOPLASTIC ACTIVITY;
CANCER IMMUNOLOGY;
CANCER SURVIVAL;
CHEMOEMBOLIZATION;
CYTOTOXIC T LYMPHOCYTE;
HEALTH CARE QUALITY;
HEPATITIS C;
HUMAN;
LIVER CELL CARCINOMA;
MOLECULARLY TARGETED THERAPY;
MONOTHERAPY;
NOTE;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SYSTEMIC THERAPY;
T LYMPHOCYTE ACTIVATION;
ANALOGS AND DERIVATIVES;
DRUG RESISTANCE;
LIVER TUMOR;
ANTINEOPLASTIC AGENTS;
CARCINOMA, HEPATOCELLULAR;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
LIVER NEOPLASMS;
NIACINAMIDE;
PHENYLUREA COMPOUNDS;
PROTEIN KINASE INHIBITORS;
PYRIDINES;
|
EID: 85018638275
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(17)31044-9 Document Type: Note |
Times cited : (14)
|
References (11)
|